Department of Rheumatology, Jan van Breemen Research Institute, Reade P.O. Box 58271, 1040 HG, Amsterdam, The Netherlands.
Curr Pharm Des. 2014;20(4):496-9. doi: 10.2174/13816128113199990386.
Rituximab is an anti-CD20 monoclonal antibody often used in the treatment of rheumatoid arthritis (RA). Infusion reactions sometimes develop following rituximab administration. Delayed complications are rare. Acute coronary syndromes are listed as sideeffects of rituximab therapy. We report two cases of acute myocardial infarction following rituximab therapy for RA and review the literature regarding cardiac events in patients treated with rituximab. We would like to raise awareness of this possible complication in patients treated with rituximab.
利妥昔单抗是一种抗 CD20 单克隆抗体，常用于治疗类风湿关节炎（RA）。利妥昔单抗给药后有时会发生输注反应。迟发性并发症罕见。急性冠状动脉综合征被列为利妥昔单抗治疗的副作用。我们报告了两例 RA 患者接受利妥昔单抗治疗后发生急性心肌梗死的病例，并回顾了利妥昔单抗治疗患者心脏事件的文献。我们希望提高接受利妥昔单抗治疗的患者对此种可能并发症的认识。
